Clinical Trial Update: Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

View source ↗

Summary

A completed study comparing Ga-68 PSMA PET/CT versus F-18 NaF PET/CT for detecting bone metastases in prostate cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Fluorine-18 Sodium Fluoride (F-18 NaF) (Fluorine-18 labeled sodium fluoride radiotracer)
• Ga-68 PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical imaging agent)

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Prostate Cancer | Status: COMPLETED